...
首页> 外文期刊>European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology >Pancreatoduodenectomy associated complications influence cancer recurrence and time interval to death
【24h】

Pancreatoduodenectomy associated complications influence cancer recurrence and time interval to death

机译:胰十二指肠切除术相关并发症影响癌症复发和死亡时间间隔

获取原文
获取原文并翻译 | 示例

摘要

Background Resection is the only life-prolonging option for pancreatic or periampullary cancer. Cell-mediated immunity might reduce progression of metastasis or local recurrence likelihood, but surgery associated morbidity can suppress this immunity. The aim of this study was to examine the influence of complications on cancer specific survival after pancreatoduodenectomy (PD) for pancreatic and periampullary cancer. Method 517 consecutive patients who underwent PD for pancreatic or periampullary adenocarcinoma were analysed. Results After median follow-up of 24 (14-44) months, 377 (73%) patients had died from progressive disease, 140 (27%) were alive. Median survival for pancreatic adenocarcinoma was 22 (18-25) months following an uncomplicated postoperative course versus 16 (13-19) months for patients with major surgical complications (p = 0.021). Multivariable Cox regression analysis demonstrated that microscopically residual disease (R1), complications, and adjuvant therapy were independent factors for recurrence. Within the R1 group, survival for patients with complications was even more limited, 9.7 (8.3-11.0) versus 18.7 (15.0-22.5) for those without (p < 0.001). For patients with R1 resection complications was the only independent predictor for a shorter time interval to death (hazard ratio 1.96; 95% CI 1.16-3.30). Complications did not influence survival of patients with periampullary adenocarcinoma. Conclusion Complications after resection are independently related to an impaired survival following PD for pancreatic, but not periampullary cancer. The effect is even more dramatic in patients who had an R1 resection. Although the relation is not causal per se, the findings support the hypothesis of a complication-induced, compromised immunity rendering patients more susceptible for recurrent disease.
机译:背景切除术是胰腺癌或壶腹癌的唯一延长寿命的选择。细胞介导的免疫可能减少转移的进展或局部复发的可能性,但与手术相关的发病率可以抑制这种免疫。这项研究的目的是检查胰腺十二指肠切除术(PD)后并发症对胰腺十二指肠切除术(PD)后癌症特异性存活的影响。方法对517例因胰腺癌或壶腹周围腺癌行PD的患者进行分析。结果在中位随访24(14-44)个月后,有377例(73%)患者死于进行性疾病,有140例(27%)活着。术后无并发症的胰腺腺癌的中位生存期为22(18-25)个月,而具有重大外科手术并发症的患者为16(13-19)个月(p = 0.021)。多变量Cox回归分析表明,镜下残留疾病(R1),并发症和辅助治疗是复发的独立因素。在R1组中,有并发症的患者的生存率受到更大的限制,没有并发症的患者的生存率为9.7(8.3-11.0),而无并发症的患者为18.7(15.0-22.5)(p <0.001)。对于R1切除患者,并发症是缩短死亡时间间隔的唯一独立预测因子(危险比1.96; 95%CI 1.16-3.30)。并发症并不影响壶腹周围腺癌患者的生存。结论胰腺癌切除术后并发症与PD术后生存受损独立相关,但壶腹周围癌无关。在接受R1切除术的患者中,这种作用更为明显。尽管这种关系本身不是因果关系,但该发现支持了由并发症引起的免疫力下降的假说,使患者更容易复发疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号